Nexalin Technology reveals new cognitive improvements in Alzheimer’s patients
News provided byNexalin Technology, Inc · 2 min read
HOUSTON, September 3, 2026 (GLOBE NEWSWIRE), Nexalin Technology, Inc. (Nasdaq: NXL) has revealed new findings from a secondary analysis of data from its previously published clinical trial. The analysis, conducted on the Alzheimer’s Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) data, has uncovered previously unreported improvements in memory, comprehension, and language function among Alzheimer’s patients treated with the company’s proprietary 15 milliamp (mA) Gen-2 SYNC™ neurostimulation device.
The initial trial, a randomized, double-blind, sham-controlled clinical study, evaluated the efficacy of Nexalin’s neurostimulation device in mild Alzheimer’s disease patients. The new analysis, published in the Journal of Alzheimer’s Disease and Radiology, identified specific cognitive improvements not evident in the overall composite score. Among the 20 evaluable active-arm participants, half achieved a clinically meaningful improvement of four or more points on the ADAS-Cog, with the largest gains observed in those with the greatest cognitive impairment at the start of the trial.
These findings are set to inform the design of Nexalin’s planned U.S. Alzheimer’s pilot study, which will use the Gen-2 SYNC™ console. The secondary analysis highlighted improvements in distinct cognitive domains, including recognition memory, comprehension of spoken language, spoken language ability, word-finding, and constructional praxis, three months after treatment ended. The results suggest a potential relationship between baseline disease severity and treatment response.
“The value of this work is that it tells us where to look next,” said Mark White, CEO of Nexalin Technology. “Our published trial demonstrated significant improvements versus sham on the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), with corresponding changes on brain imaging. The item-level ADAS-Cog analysis now gives us a more granular map of the cognitive domains in which responses were concentrated, and which patients responded most. We expect these insights will directly shape endpoint selection and patient-selection strategy as we advance our planned U.S. pilot study with the FDA.”
Dr. David Owens, Chief Medical Officer of Nexalin Technology, added, “Composite scales such as the ADAS-Cog are essential tools, but they can obscure domain-specific effects, particularly in smaller studies. Examining the data beneath the composite at the item level is a standard and appropriate way to generate hypotheses for the next stage of clinical development. We expect these observations to help us design a more focused and rigorous study, including how we select patients and define endpoints.”
The Company expects to incorporate these findings into the protocol design for its planned U.S. pilot study of the Gen-2 SYNC console in Alzheimer’s disease, building on the feedback received in the Company’s Q-Submission meeting with the FDA, which was announced on December 3, 2025. The broader FDA strategy outlined in the Company’s April 15, 2026 announcement will also guide the development.
Nexalin Technology, Inc. designs and develops non-invasive neurostimulation products to combat mental health issues, with the Gen-2 15 milliamp neurostimulation device having been approved in China, Brazil, Oman, and Israel. The company intends to provide further updates as its U.S. Alzheimer’s program advances.
The findings from this secondary analysis underscore the importance of detailed cognitive assessments in understanding the specific benefits of neurostimulation devices in Alzheimer’s patients.